Keyphrases
Chemoradiotherapy
100%
Disease-associated
100%
Head-and-neck Cancer
100%
Advanced Stage
100%
Disease Outcome
100%
Platinum-based
100%
HPV Negative
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
83%
Cisplatin
50%
Overall Survival
50%
Clinical Variables
33%
Distant Metastasis
33%
Clinical Management
33%
Multicenter Cohort
33%
Cisplatin Toxicity
33%
Meta-analysis
16%
C-index
16%
Clinical Treatment
16%
Treatment Results
16%
Confounding
16%
Weight Loss
16%
Treatment Protocol
16%
Treatment Parameters
16%
5-year Follow-up
16%
Clinical Parameters
16%
Locally Advanced
16%
Retrospective Data
16%
Curative Intent
16%
Locoregional Control
16%
Prognostic Factors
16%
TNM Staging
16%
HPV Status
16%
Pharynx
16%
Laryngeal Cancer
16%
Radiotherapy Techniques
16%
Tumor Site
16%
Stage III-IV
16%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
16%
Regional Lymph Nodes
16%
Real-world Outcomes
16%
Prognostic Model
16%
Number of Cycles
16%
Less Toxic
16%
Boosting Method
16%
Definitive Chemoradiotherapy (dCRT)
16%
N3 Stage
16%
Oropharyngeal Tumor
16%
Radiosensitization
16%
Cisplatin Dose
16%
Cumulative Cisplatin Dose
16%
INIS
diseases
100%
patients
100%
cancer
100%
combined therapy
100%
platinum
100%
carcinomas
71%
doses
42%
toxicity
42%
data
28%
tumors
28%
comparative evaluations
28%
radiotherapy
28%
management
28%
metastases
28%
control
14%
losses
14%
lymph nodes
14%
weight
14%
gold
14%
radiosensitizers
14%
larynx
14%
pharynx
14%
Medicine and Dentistry
Chemoradiotherapy
100%
Head and Neck Cancer
100%
Cisplatin
100%
Diseases
100%
Head and Neck Squamous Cell Carcinoma
71%
Overall Survival
42%
Clinical Management
28%
Distant Metastasis
28%
Lymph Node
14%
Neoplasm
14%
Meta-Analysis
14%
Prognostic Factor
14%
Radiosensitizer
14%
Laryngeal Cancer
14%
Larynx
14%
Intensity Modulated Radiation Therapy
14%
Pharynx
14%
Oropharynx Carcinoma
14%
Oropharynx Tumor
14%
Radiation Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Chemoradiation Therapy
100%
Head and Neck Cancer
100%
Diseases
100%
Head and Neck Squamous Cell Carcinoma
71%
Overall Survival
42%
Distant Metastasis
28%
Neoplasm
14%
Radiosensitizing Agent
14%
Larynx Cancer
14%
Oropharynx Cancer
14%
Oropharynx Carcinoma
14%
Oropharynx Tumor
14%